ArticleEJHaem2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma.British journal of haematology · 2026Article
- Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma.British journal of haematology · 2026Article
- Comment on "how the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes".The oncologist · 2026Article
- A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.Haematologica · 2025Article
- Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.Blood cancer journal · 2025Article
- Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma.Journal of clinical medicine · 2025Article
- Review
- Review
- Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy.Frontiers in oncology · 2025Review
- Options at the time of relapse after anti-BCMA therapy.Hematology. American Society of Hematology. Education Program · 2023Article
- Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.Blood cancer journal · 2023Observational
- Review
- Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.Targeted oncology · 2023Review
- Article
- Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors.Frontiers in immunology · 2023Review
- Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.EJHaem · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients' prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.